Ertugliflozin plus sitagliptin more effective than monotherapy with either | ADA
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Ertugliflozin plus sitagliptin is more effective than either treatment alone for the reduction of HbA1c and fasting plasma glucose (FPG).
Why this matters
Ertugliflozin is an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor in development for the treatment of type 2 diabetes. (T2D).
Researchers with the VERTIS FACTORIAL Trial extension conducted this double-blind phase 3 trial, in which 1233 participants with HbA1c 7.5%-11.0% on stable metformin monotherapy ≥1500 mg/d were randomized into five groups.
Ertugliflozin plus sitagliptin combinations were compared with corresponding ertugliflozin doses (5 mg or 15 mg) or sitagliptin alone.
The primary outcome was at wk 26; treatment was continued in a...